B
Bull
Bull · 25%AAPG
$58.30
Scenario price
$15.370
+0.712 (+4.63%)At close
Loading chart…
- High
- 15.530
- Open
- 14.800
- VWAP
- 15.23
- Volume
- 15.09K
- Mkt Cap
- —
- Low
- 14.800
- Amount
- 229.90K
- EV/EBITDA, TTM
- -0.44
Ascentage Pharma Group International is an investment holding company primarily engaged in the discovery, development, and commercialization of therapies for hematologic malignancies. The Company's main products include Olverembatinib (HQP1351), Lisaftoclax (APG-2575), Alrizomadlin (APG-115), Pelcitoclax (APG-1252), APG-5918, and APG-2449. The Company's products are primarily used to treat chronic myeloid leukemia (CML), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), acute lymphoblastic leukemia (ALL), myelodysplastic syndrome (MDS) and multiple myeloma (MM). The Company primarily conducts its businesses in domestic market.
AI analysis of Ascentage Pharma Group International (AAPG)
BuyAscentage Pharma Group International (AAPG) appears to be a good buy right now due to its recent positive earnings report, where it exceeded EPS expectations by $1.66, and a forward P/E ratio of 10.06, indicating potential for growth. The stock has shown a recent 5-day change of +4.20%, suggesting a positive momentum. However, the main risk is the significant year-to-date decline of -41.71%, which indicates volatility and potential challenges ahead.
Valuation Metrics
The current forward P/E ratio for Ascentage Pharma Group International (AAPG) is 10.06, compared to its 5-year average forward P/E of -23.02.
Alphio AI Price Scenarios for AAPG
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
Events Timeline
News
6.010-14CNBCKey Wall Street Rating Changes on Wednesday
9.508-19NewsfilterAscentage Pharma Reports 29% Revenue Growth in H1 2026
5.008-02GlobenewswireAscentage Pharma Appoints New Executives to Strengthen Global Business
- 5.008-02Newsfilter
Ascentage Pharma Appoints New Executives to Strengthen Global Business
8.507-26GlobenewswireDr. Dajun Yang Named No. 3 on The Medicine Maker Power List 2026
AAPG FAQ — answered by Alphio AI
Ascentage Pharma Group International is an investment holding company primarily engaged in the discovery, development, and commercialization of therapies for hematologic malignancies. The Company's main products include Olverembatinib (HQP1351), Lisaftoclax (APG-2575), Alrizomadlin (APG-115), Pelcitoclax (APG-1252), APG-5918, and APG-2449. The Company's products are primarily used to treat chronic myeloid leukemia (CML), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), acute lymphoblastic leukemia (ALL), myelodysplastic syndrome (MDS) and multiple myeloma (MM). The Company primarily conducts its businesses in domestic market. It operates in the Healthcare sector.
Ascentage Pharma Group International (AAPG) appears to be a good buy right now due to its recent positive earnings report, where it exceeded EPS expectations by $1.66, and a forward P/E ratio of 10.06, indicating potential for growth. The stock has shown a recent 5-day change of +4.20%, suggesting a positive momentum. However, the main risk is the significant year-to-date decline of -41.71%, which indicates volatility and potential challenges ahead.
Community
More ↗No posts yet
Sign up or log in to join the discussionThis page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.